Clara Hwang, MD

Clara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.

Clara Hwang, MD, discusses unmet needs in patients with nonmetastatic prostate cancer who then progress on novel agents and develop metastatic disease.

Clara Hwang, MD, discusses risk stratification methods used to assess the risk of metastatic disease in patients with nonmetastatic prostate cancer.

Clara Hwang, MD, highlights agents that the FDA has approved for use in patients with nonmetastatic castration-resistant prostate cancer, such as apalutamide, enzalutamide, and darolutamide.

Clara Hwang, MD, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and bone metastases.

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Clara Hwang, MD, discusses the utility of antiandrogens in patients with metastatic prostate cancer.

Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the state of treatment in metastatic prostate cancer.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.